Advertisement

Related Videos

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Deborah Collyar: What's In It for Patients?

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Advertisement

Advertisement




Oct
30
Today In Oncology
Disitamab Vedotin Plus Tislelizumab Shows Activity in Very High–Risk Non–Muscle-Invasive Bladder Cancer
How Medicare Advantage and Traditional Medicare Influence Palliative and Hospice Care Implementation
Tarlatamab Plus Durvalumab as First-Line Maintenance in Extensive-Stage SCLC
TALENT Neoadjuvant T-DXd in HER2-Low Early Breast Cancer
Adding a Chatbot to Cancer Predisposition Visits Improves Risk Knowledge in AYAs
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo